A Phase 2, Open-Label Study of the Safety and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck, Lung, or Esophagus

Trial Profile

A Phase 2, Open-Label Study of the Safety and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck, Lung, or Esophagus

Discontinued
Phase of Trial: Phase II

Latest Information Update: 07 Apr 2017

At a glance

  • Drugs Selinexor (Primary)
  • Indications Head and neck cancer; Lung cancer; Oesophageal cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Acronyms STARRS
  • Sponsors Karyopharm Therapeutics
  • Most Recent Events

    • 26 May 2016 Planned End Date changed from 1 Apr 2016 to 1 Jun 2016.
    • 23 Mar 2016 Status changed from active, no longer recruiting to discontinued as per ClinicalTrials.gov record.
    • 22 Feb 2016 Planned End Date changed from 1 Feb 2016 to 1 Mar 2016, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top